Derivatives Incorporating Acridine, Pyrrole, and Thiazolidine Rings as Promising Antitumor Agents.
HR MS spectroscopy
IR spectroscopy
NMR spectroscopy
X-ray analysis
acridine
antiproliferative activity
pyrrole
thiazolidine
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
14 Sep 2023
14 Sep 2023
Historique:
received:
27
08
2023
revised:
10
09
2023
accepted:
12
09
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Derivatives combining acridine, pyrrole, and thiazolidine rings have emerged as promising candidates in the field of antitumor drug discovery. This paper aims to highlight the importance of these three structural motifs in developing potent and selective anticancer agents. The integration of these rings within a single molecule offers the potential for synergistic effects, targeting multiple pathways involved in tumor growth and progression. Spiro derivatives were efficiently synthesized in a two-step process starting from isothiocyanates and 2-cyanoacetohydrazide. The thiourea side chain in spiro derivatives was utilized as a key component for the construction of the thiazolidine-4-one ring through regioselective reactions with bifunctional reagents, namely methyl-bromoacetate, dietyl-acetylenedicarboxylate, ethyl-2-bromopropionate, and ethyl-2-bromovalerate. These reactions resulted in the formation of a single regioisomeric product for each derivative. Advanced spectroscopic techniques, including 1D and 2D NMR, FT-IR, HRMS, and single-crystal analysis, were employed to meticulously characterize the chemical structures of the synthesized derivatives. Furthermore, the influence of these derivatives on the metabolic activity of various cancer cell lines was assessed, with IC
Identifiants
pubmed: 37764394
pii: molecules28186616
doi: 10.3390/molecules28186616
pmc: PMC10537105
pii:
doi:
Substances chimiques
Acridines
0
Pyrroles
0
Thiazolidines
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Molecules. 2022 Apr 14;27(8):
pubmed: 35458736
Bioorg Chem. 2022 Nov;128:106075
pubmed: 35952447
Magn Reson Chem. 2020 Feb;58(2):204-214
pubmed: 31758569
Magn Reson Chem. 2016 Jan;54(1):8-16
pubmed: 26365601
Cancers (Basel). 2022 Oct 22;14(21):
pubmed: 36358593
Acta Crystallogr A Found Adv. 2015 Jan;71(Pt 1):3-8
pubmed: 25537383
Sci Rep. 2023 Mar 1;13(1):3431
pubmed: 36859494
Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):3-8
pubmed: 25567568
Pharmaceutics. 2022 Feb 24;14(3):
pubmed: 35335879
Oncol Rep. 2020 Feb;43(2):711-717
pubmed: 31894283
Toxicol Appl Pharmacol. 2023 Sep 1;474:116625
pubmed: 37451322
Int J Mol Sci. 2022 Sep 21;23(19):
pubmed: 36232355
Front Pharmacol. 2022 Oct 14;13:1040163
pubmed: 36313280
Cancers (Basel). 2022 Sep 21;14(19):
pubmed: 36230492
J Enzyme Inhib Med Chem. 2022 Dec;37(1):1821-1837
pubmed: 35762086
Molecules. 2022 Apr 30;27(9):
pubmed: 35566243
Bioorg Chem. 2022 Feb;119:105543
pubmed: 34929515
Acta Crystallogr D Biol Crystallogr. 2009 Feb;65(Pt 2):148-55
pubmed: 19171970
Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016 Apr;72(Pt 2):171-9
pubmed: 27048719
Int J Mol Sci. 2022 Dec 21;24(1):
pubmed: 36613504
Org Lett. 2012 Jul 6;14(13):3256-9
pubmed: 22686446
Nat Prod Rep. 2016 Mar;33(3):432-55
pubmed: 26673733
Pharmacol Rep. 2022 Jun;74(3):545-554
pubmed: 35297003
Bioorg Med Chem Lett. 2022 Aug 15;70:128804
pubmed: 35598791
ChemMedChem. 2023 Apr 3;18(7):e202200666
pubmed: 36734215
Molecules. 2022 Apr 30;27(9):
pubmed: 35566236
Int J Mol Sci. 2022 Oct 14;23(20):
pubmed: 36293123
Bioorg Chem. 2023 Apr;133:106411
pubmed: 36801792
Int J Mol Sci. 2022 Oct 28;23(21):
pubmed: 36361924